Wells Fargo & Company MN raised its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 138.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 95,547 shares of the biopharmaceutical company’s stock after acquiring an additional 55,463 shares during the quarter. Wells Fargo & Company MN owned about 0.20% of Agios Pharmaceuticals worth $4,915,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Blue Sky Asset Management LLC bought a new stake in Agios Pharmaceuticals during the first quarter valued at $129,000. Russell Investments Group Ltd. boosted its position in Agios Pharmaceuticals by 163.9% during the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 1,583 shares during the last quarter. Aperio Group LLC bought a new stake in Agios Pharmaceuticals during the second quarter valued at $206,000. Soros Fund Management LLC bought a new stake in Agios Pharmaceuticals during the first quarter valued at $228,000. Finally, Parametrica Management Ltd bought a new stake in Agios Pharmaceuticals during the second quarter valued at $228,000. 94.40% of the stock is currently owned by institutional investors and hedge funds.

AGIO has been the topic of a number of research analyst reports. Janney Montgomery Scott cut shares of Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, June 26th. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Royal Bank Of Canada initiated coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price target on the stock. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating and set a $76.00 price target on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $75.20.

ILLEGAL ACTIVITY NOTICE: “Agios Pharmaceuticals, Inc. (AGIO) Shares Bought by Wells Fargo & Company MN” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/13/agios-pharmaceuticals-inc-agio-shares-bought-by-wells-fargo-company-mn.html.

Agios Pharmaceuticals, Inc. (AGIO) opened at 72.33 on Friday. Agios Pharmaceuticals, Inc. has a one year low of $39.24 and a one year high of $72.50. The stock’s 50 day moving average is $65.62 and its 200 day moving average is $56.61. The firm’s market cap is $3.50 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.21). The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The company’s revenue for the quarter was up 62.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.47) EPS. On average, analysts predict that Agios Pharmaceuticals, Inc. will post ($7.08) earnings per share for the current fiscal year.

In related news, Director Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $56.36, for a total transaction of $507,240.00. Following the completion of the transaction, the director now directly owns 86,697 shares of the company’s stock, valued at approximately $4,886,242.92. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO David P. Schenkein sold 80,000 shares of Agios Pharmaceuticals stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $70.14, for a total transaction of $5,611,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 228,408 shares of company stock worth $14,976,478 in the last ninety days. Insiders own 10.55% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.